key: cord-0897318-n2atn6nf
authors: Paul, Prannoy
title: Cardiac Troponin-I may be a predictor of complications and mortality in COVID-19 patients.
date: 2020-05-07
journal: Curr Med Res Pract
DOI: 10.1016/j.cmrp.2020.05.001
sha: 04138d59b070c524b19d8fb12a5ce72e07208e3b
doc_id: 897318
cord_uid: n2atn6nf

nan

Myocarditis caused by viruses may be focal or global, and might result in inflammation and necrosis of the myocardial wall, eventually resulting in ventricular dysfunction. Chest pain in a patient with influenza like symptoms, with clinical evidence of acute coronary syndrome on ECG or lab values, and wall motion abnormalities, without any evidence of obstruction in coronary angiography should arouse the suspicion of a focal viral myocarditis [6] Laboratory data from China has pointed out that among patients diagnosed with COVID -19, the values of cardiac troponin I (cTnI), were significantly high among patients with severe disease than in the ones with milder forms of the disease [5] .

Though recent literature shows that marginal elevation of cardiac Troponin I (cTnI) is common in most patients infected with COVID -19, only about 8 to 12 percent of cases show values above the 99 th percentile of the upper limit. Also significant elevation in the values of cTnI was noted in patients with severe form of the disease who progressed to major complications like multi organ dysfunction and death [7] .

Cardiac involvement in these cases maybe due to direct dissemination of the virus into the blood stream from the lungs, or due to an exaggerated immune response to the virus, resulting in myocardial injury. The second theory may justify the use of corticosteroids to attenuate the inflammatory response, as was seen in some cases of COVID -19 with myocarditis who improved with the use of steroids [8] .

Hence it may be reasonable at this point to consider that significant elevation in the values of cardiac Tropoinin I (cTnI) may be linked to severe disease and life threatening complications in patients infected with COVID -19. We hypothesize that measurement of cTnI values at the time of hospital admission and following up the values longitudinally may help us identify the subset of patients with COVID 19, who may progress towards severe complications and death. This might help in focussing more on this subset of patients which in turn might help in lowering the morbidity and mortality associated with the current pandemic worldwide. Further studies on this topic is urgently required which will help in further investigations into this topic and help in controlling the current outbreak and deaths associated with it worldwide.

World Health Organization

Which lessons shall we learn from the 2019 novel coronavirus outbreak?

Cardiac complications in patients with communityacquired pneumonia: a systematic review and meta-analysis of observational studies

Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)

Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Progress in cardiovascular diseases

Molecular biology and pathogenesis of viral myocarditis

Laboratory abnormalities in patients with COVID-2019 infection. Clinical Chemistry and Laboratory Medicine (CCLM)

Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)

The authors declare no conflict of interest.

No funding received for this work.